-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2

Benzinga·07/30/2026 18:23:17
Listen to the news
Piper Sandler analyst Edward Tenthoff downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $58 to $2.